New Zealand’s June Medical-Cannabis Supply Stayed Decisively THC-Led

June 2026 pack data shows a medical market led by THC-containing products

New Zealand’s latest Ministry of Health supply update puts a clear number on a question that often gets answered with anecdotes. In June 2026, the country supplied 24,389 packs of unapproved medicinal-cannabis products. Of those, 18,845 were THC-only packs, 1,250 contained both THC and CBD, and 4,294 were CBD-only.

That means THC-containing products accounted for 20,095 packs in the month, or just over 82 percent of the total. CBD-only products made up about 18 percent. On the simplest reading, the domestic medical market is not currently being led by CBD on its own. It is being led by products that contain THC.

That is news now because the Ministry updated this supply dataset on 1 September 2026 and, on the same day, refreshed its list of current medicinal-cannabis licence holders. That roster shows 45 current licence holders. Read together, the two updates do something more useful than a licence count on its own. They show both the regulated capacity that exists on paper and the product mix that is actually moving through the medical channel.

For cultivators, importers, manufacturers and capital providers, that matters. A licence list can suggest an industry is building out. A supply dataset shows whether that build-out is pointed at the products patients are receiving. In New Zealand’s case, the latest public signal says the market remains decisively THC-led.

The numbers also matter because the dataset is tracking unapproved medicinal-cannabis products. In practical terms, that means products supplied within the medical framework without having full medicine approval. The word unapproved here does not mean illicit. It identifies a route of lawful medical supply that sits inside New Zealand’s medicinal-cannabis system.

There are limits to what can be taken from a monthly pack count. The data does not show the number of patients, the value of those packs, the dosage forms behind them, or whether the stock was grown and made locally or brought in from overseas. It also does not tell the market why prescribers chose one cannabinoid profile over another. But for all those gaps, the June reading is still unusually concrete. It shows what was dispensed by pack type, and it does so in a way that directly tests assumptions about demand.

One assumption it tests is the idea that medical cannabis in a tightly regulated market naturally resolves into a CBD-dominant business. New Zealand’s June data points the other way. Even after setting aside the mixed THC-and-CBD category, THC-only packs outnumbered CBD-only packs by more than four to one.

The scheme separates licences, supply rights and cross-border movement

To understand why these pack numbers matter, it helps to understand what the licence list does and does not say. New Zealand’s Ministry of Health treats medicinal cannabis as a regulated chain rather than a single permission slip. The industry framework distinguishes between the different activities needed to get product from plant or imported consignment into lawful medical supply.

That distinction is easy to miss when licence counts are discussed in isolation. A current licence holder is not automatically a business with saleable stock moving to patients. A company may hold a licence somewhere in the chain, but still depend on further permissions, assessed products, manufacturing steps, release processes, or cross-border approvals before it can meet real demand.

The Ministry’s supply guidance is important here because it sets out what is required for domestic supply activity and what product-assessment obligations apply. In plain terms, having cultivation, extraction or manufacturing capability is not enough by itself. A business also needs the right authority to supply, and the product it supplies must satisfy the relevant regulatory checks for that route.

That is one reason the June pack mix carries more weight than the licence roster alone. The roster shows 45 current licence holders as of 1 September. The supply data shows which broad product categories are actually reaching the medical channel. Put differently, the licence list measures presence in the system. The pack data measures market expression inside the system.

The import and export rules add another layer. New Zealand requires licensing for medicinal-cannabis consignments moving across the border. In practice, this means demand shown in the June pack data could have been met by domestic output, by imports, or by a combination of both, depending on what operators had available and authorised at the time. That matters because a country can have a growing local licence base while a meaningful share of the supply mix is still fulfilled from abroad.

This is why the latest update is useful without being complete. It does not identify the origin of each supplied pack, but it does narrow the field of speculation. If THC-containing products make up more than four-fifths of monthly packs, then any operator building capacity around New Zealand’s medical market has to take that mix seriously, whether the plan is local cultivation, contract manufacturing, white-label supply, or import distribution.

The structure of the dataset also matters. It records packs, not grams, millilitres, prescriptions or revenue. A pack is a clean administrative unit, but it is not a full commercial unit. One pack can differ materially from another in strength, quantity and price. That means the June data is strong evidence of directional demand by cannabinoid profile, but not a complete measure of market value or clinical intensity.

Even with that limitation, pack data has one advantage over broader market narratives. It forces the discussion away from abstract growth stories and back onto the physical products that are being supplied. In regulated cannabis markets, that is often where the real commercial story sits.

Forty-five licence holders now have a harder demand signal to ignore

The immediate consequence of the June figures is not that every licence holder suddenly needs a new strategy. It is that the room for vague positioning gets smaller. A market supplying 20,095 THC-containing packs in a month and 4,294 CBD-only packs is sending a clearer signal than many regulated cannabis markets ever publish.

For cultivators, the implication is straightforward. Product demand is not simply a question of total plant output. It is a question of what cannabinoid profile the downstream medical channel is taking. Genetics, crop planning, extraction pathways and inventory assumptions all look different when THC-containing supply is dominant.

For manufacturers, the same logic applies further along the chain. If the market is absorbing far more THC-only and THC-and-CBD packs than CBD-only packs, production scheduling, ingredient sourcing, fill-and-finish capacity and compliance planning need to match that. A technically capable facility can still be commercially misaligned if it is set up around the wrong mix.

For importers, the update is particularly valuable because New Zealand’s rules still make cross-border logistics a live part of the market. Where domestic producers cannot supply the needed formats, strengths or cannabinoid profiles at the right time, imports remain a lawful route subject to the required consignment permissions. The June figures do not prove import dependence, but they do identify where import capability is most likely to matter if local supply is thin or uneven.

For investors and lenders, the pairing of the two Ministry updates is a useful discipline. Forty-five current licence holders may sound like a substantial base in a relatively small country. But a licence count is not the same as an addressable market, and an addressable market is not the same as a balanced one. If monthly supply is concentrated in THC-containing categories, then some parts of installed or proposed capacity may be better aligned than others.

That matters because New Zealand’s regulated medical market is not infinitely broad. The June total of 24,389 packs is meaningful, but it is not so large that every business model can be right at once. In a market of this size, concentration in one broad product segment can shape margins, throughput and inventory risk very quickly.

The update also matters for medical businesses closer to dispensing. The supply data is one of the clearest public windows into what prescribers and patients are actually receiving through the legal pathway. It is not a direct read on clinical preference, because prescribing decisions depend on many factors that do not appear in the dataset. But it is still evidence that the market outcome, at least in June, was led by THC-containing packs rather than CBD-only supply.

There is also a policy point here. New Zealand’s public reporting offers a better demand read than many jurisdictions provide. The Ministry publishes supply data and a current licence-holder roster, which gives outside observers a way to compare regulated capacity with visible supply. Yet the transparency is still partial. The data does not show domestic versus imported product, it does not break out commercial value, and it does not show whether some categories are concentrated among a small number of operators.

Those gaps matter because they affect how the June numbers should be interpreted. A THC-heavy pack mix could reflect stable patient demand, prescriber preference, product availability, pricing, reimbursement realities, import timing, or some combination of them. The public data does not settle that question. What it does settle is the shape of supply at the point reported by the Ministry.

That alone is enough to change how the market should be discussed. Any conversation about New Zealand medicinal cannabis that treats CBD-only products as the clear centre of gravity now looks out of step with the latest official numbers.

The real test is whether licensed capacity matches the products patients are receiving

The harder edge of this update is not the headline ratio. It is what that ratio says about execution.

New Zealand now has 45 current medicinal-cannabis licence holders on the Ministry’s list. That is a sign of institutional depth. It shows the country has built a regulated base of businesses prepared to operate inside the medical framework. But a regulated base is not the same as a market fit. If the products actually supplied are overwhelmingly THC-containing, then the industry’s next test is not how many licence holders exist. It is whether enough of those licence holders are set up to serve that demand reliably and lawfully.

That is a stricter test than simple expansion. It reaches into formulation strategy, release capability, supply permissions, stock planning and border execution. It also reaches into capital allocation. Businesses that are misread on the demand mix can spend heavily on capacity that looks credible in a licensing document and weak in real distribution.

The June data does not tell the whole story, and it should not be pressed beyond what it can bear. It does not identify margins. It does not tell the market whether June was typical or distorted by timing. It does not show how much of the THC-containing volume sat in one format or one supply route. But it does something more important than that. It removes a layer of ambiguity around what the market is currently taking.

That leaves a sober conclusion. New Zealand’s medical cannabis system is now transparent enough to expose strategic drift. Operators can no longer rely on the fact of being licensed as evidence that they are aligned with demand. The Ministry’s own figures show where the packs are going.

In that sense, the latest update is less a snapshot than a sorting mechanism. It separates businesses that are participating in a regulated industry from businesses that are positioned for the product mix that industry is actually dispensing. As of June 2026, those are not automatically the same thing.